We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting
MINNEAPOLIS, April 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 at McCormick Place Convention Center in Chicago, IL. Bio-Techne's booths will feature its oncology research portfolio spanning early discovery, translational research, and cell and gene therapy development.
AACR is recognized as one of the world's most influential cancer research conferences, convening global experts to exchange groundbreaking discoveries and innovations in cancer science and medicine. Bio-Techne will engage with these researchers and industry professionals to highlight its cutting-edge solutions that empower scientific progress across the oncology landscape.
At booth #3049, Bio-Techne will feature its comprehensive portfolio, including high-performance proteins, antibodies, small molecules, cell culture reagents, immunoassays, automated proteomic analysis platforms, and spatial multiomic solutions. These technologies are designed to drive advancements in oncology research, accelerate immune cell therapy development, and support the creation of next-generation diagnostic tools. Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will feature its complete solution for accelerating spatial multiomic research, including its protease-free workflows across the RNAscope™ spatial portfolio. To support the expanded capabilities for multiomic detection on the Leica Bond RX, we will showcase scientific posters and an evening reception on April 27th co-hosted by ACD, Leica Biosystems and Indica Labs.
At booth #3249, Lunaphore, one of Bio-Techne's spatial biology brands, will present its enhanced end-to-end portfolio that offers high-value spatial biology solutions for the translational research community. Lunaphore's latest advancements include the launch of the fully-automated, same-section multiomics application for fixed-frozen tissue. Additionally, Lunaphore will bring together the spatial biology community at an exclusive dinner reception on April 28, held in affiliation with AACR, providing a unique opportunity to connect with leaders in the field of multiomics, and explore Lunaphore's upcoming releases, including innovative tools for HORIZON™ image analysis software.
"As cancer research advances at an unprecedented pace, Bio-Techne remains committed to providing scientists with the tools they need to drive discovery and innovation," said Kim Kelderman, Bio-Techne's President and Chief Executive Officer. "Our solutions empower researchers at every stage—from fundamental science to translational applications—helping to shape the future of precision medicine and next-generation cancer therapies. We are excited to connect with the scientific community at AACR to explore new possibilities in the fight against cancer."
Bio-Techne Presentations and Poster Presentations:
Protein Quantitation for Characterization of Potential Cancer Therapeutics in Early Discovery and Mechanism of Action Insights in Translational Studies Tuesday, April 29 | 10:00 – 11:00 AM Exhibit Hall, Spotlight Theater A
Evaluation of IDH1, EGFR, IGF1R, and Ki67 Biomarkers in Glioblastoma Using Lunaphore COMET™ Platform Monday, April 28 | 9:00 AM - 12:00 PM Poster Board 29 | Abstract 2093 Presenter: Jennifer Jones, Sr. Product Marketing Specialist
Multiomic Co-Detection of Proteins, mRNA and Protein-Protein Interactions Reveal PD1-PDL1 Interactions in the Tumor Microenvironment of Bladder Cancer Patients Treated with anti-PD-L1 Monday, April 28 | 9:00 AM - 12:00 PM Poster Board 3 | Abstract 2179 Presenter: Ge-Ah Kim, Sr. Scientist
Multiomic Fluorescent Co-Detection of Biomarkers in the Tumor Microenvironment Using a New RNAscope™ Assay on Roche DISCOVERY™ ULTRA Monday, April 28 | 9:00 AM - 12:00 PM Poster Board 28 | Abstract 2092 Presenter: Anushka Dikshit, Sr. Applications Manager
Identifying Immune Cell Phenotypes and Their Function by Using High Throughput Spatial Multiomics Tuesday, April 29 | 2:00 PM - 5:00 PM Poster Board 24 | Abstract 5318 Presenter: Anushka Dikshit, Sr. Applications Manager
Profiling the Tumor-Immune Landscape with a Same-Section Multiomics Assay Tuesday, April 29 | 2:00 PM - 5:00 PM Poster Board 10 | Abstract 5304 Presenter: Jacqueline Giliberti, PhD, Product Manager
Spatial Multiomics Reveals T-cell Activation and Exhaustion States in the Tumor Microenvironment Wednesday, April 30 | 9:00 AM - 12:00 PM Poster Board 12 | Abstract 6471 Presenter: Anushka Dikshit, Sr. Applications Manager
Poster Presentation In Collaboration A Novel Protease-Free Workflow for Spatial Multiomics Analysis of the Tumor Microenvironment in Breast Cancer Poster Board 21 | Abstract 170 Presenter: Dr. Tanni Rahman, HistoWiz
Dissecting the Immune Landscape in EBV+ Classical Hodgkin Lymphoma Following IL-23 Inhibition Using Single-Cell Hyperplex Immunofluorescence Analysis: A Case Report Wednesday, April 30 | 9:00 AM - 12:00 PM Poster Board 9 | Abstract 6468 Presenter: Dr. Janusz Franco-Barraza, Fox Chase Cancer Center
Translating clinically Validated Antibodies into a Multiplexed Immunofluorescent Panel for the Spatial Profiling of Lymphoid Malignancies Monday, April 28 | 2:00 PM - 5:00 PM Poster Board 4 | Abstract 2525 Presenter: Dr. Tania Pannellini, European Institute of Oncology (EIO)
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.
